Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent

Stephanie R. Rice, Melissa A.L. Vyfhuis, Katherine A. Scilla, Whitney M. Burrows, Neha Bhooshan, Mohan Suntharalingam, Martin J. Edelman, Josephine Feliciano, Shahed N. Badiyan, Charles B. Simone, Soren M. Bentzen, Steven J. Feigenberg, Pranshu Mohindra

Research output: Contribution to journalArticle

Abstract

Introduction: Population studies suggest an impact of insurance status on oncologic outcomes. We sought to explore this in a large single-institution cohort of patients with non–small-cell lung cancer (NSCLC). Materials and Methods: We retrospectively analyzed 342 consecutive patients (January 2000 to December 2013) curatively treated for stage III NSCLC. Patients were categorized by insurance status as uninsured (U), Medicare/Medicaid + Veterans Affairs (M/M + VA), or Private (P). The χ2 test was utilized to compare categorical variables. The Kaplan-Meier approach and the Cox proportional hazard models were used to analyze overall survival (OS) and freedom from recurrence (FFR). Results: Compared with M/M + VA patients, P insurance patients were more likely to be younger (P < .001), married (P < .001), Caucasian (P = .001), reside in higher median income zip codes (P < .001), have higher performance status (P < .001), and undergo consolidation chemotherapy (P < .001) and trimodality therapy (P < .001). Diagnosis to treatment was delayed > 30 days in U (67.3%), M/M + VA (68.1%), and P (52.6%) patients (P = .017). Compared with the M/M + VA and U cohorts, P insurance patients had improved OS (median/5-year: 30.7 months/34.2%, 19 months/17%, and 16.9 months/3.8%; P < .001) and FFR (median/5-year: 18.4 months/27.3%, 15.2 months/23.2%, and 11.4 months/4.8%; P = .012), respectively. On multivariate analysis, insurance status was an independent predictor for OS (P = .017) but not FFR. Conclusion: Compared with U or M/M + VA patients, P insurance patients with stage III NSCLC were more likely to be optimally diagnosed and treated, resulting in a doubling of median OS for P versus U patients. Improved access to affordable health insurance is critical to combat inequities in access to care and has potential for improvements in cancer outcomes. Our work demonstrates that insurance status is an independent predictor of overall survival in patients with stage III non–small-cell lung cancer undergoing definitive treatment. This work highlights the importance of improved access to affordable healthcare, and how lack of access has significant mortality consequences in lung cancer.

Original languageEnglish (US)
Pages (from-to)e130-e141
JournalClinical lung cancer
Volume21
Issue number3
DOIs
StatePublished - May 2020

Keywords

  • Chemoradiation
  • Disparities
  • Lung cancer
  • Trimodality
  • Uninsured

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent'. Together they form a unique fingerprint.

  • Cite this

    Rice, S. R., Vyfhuis, M. A. L., Scilla, K. A., Burrows, W. M., Bhooshan, N., Suntharalingam, M., Edelman, M. J., Feliciano, J., Badiyan, S. N., Simone, C. B., Bentzen, S. M., Feigenberg, S. J., & Mohindra, P. (2020). Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent. Clinical lung cancer, 21(3), e130-e141. https://doi.org/10.1016/j.cllc.2019.08.009